Literature DB >> 8630597

Association of chronic mucus hypersecretion with FEV1 decline and chronic obstructive pulmonary disease morbidity. Copenhagen City Heart Study Group.

J Vestbo1, E Prescott, P Lange.   

Abstract

The aim of this study was to examine the association between chronic mucus hypersecretion, and FEV1 decline, and subsequent hospitalization from chronic obstructive pulmonary disease (COPD). We used data from The Copenhagen City Heart Study on 5,354 women and 4,081 men 30 to 79 yr of age with assessment of smoking habits, respiratory symptoms, and spirometry at two surveys 5 yr apart. Information on COPD hospitalization during 8 to 10 yr of subsequent follow-up was obtained from a nationwide register. Chronic mucus hypersecretion was significantly associated with FEV1 decline; the effect was most prominent among men, where chronic mucus hypersecretion at both surveys was associated with an excess FEV1 decline of 22.8 ml/yr (95% confidence interval, 8.2 to 37.4) compared with men without mucus hypersecretion, after adjusting for age, height, weight change, and smoking; in women, the excess decline was 12.6 ml/yr (0.7-24.6). Chronic mucus hypersecretion was associated with subsequent hospitalization due to COPD after adjusting for age and smoking; relative risk was 5.3 (2.9 to 9.6) among men and 5.1 (2.5 to 10.3) among women. After further adjusting for FEV1 at the second survey, the relative risk was reduced to 2.4 (1.3 to 4.5) for men and 2.6 (1.2 to 5.3) for women. Chronic mucus hypersecretion was significantly and consistently associated with both an excess FEV1 decline and an increased risk of subsequent hospitalization because of COPD.

Entities:  

Mesh:

Year:  1996        PMID: 8630597     DOI: 10.1164/ajrccm.153.5.8630597

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  179 in total

1.  Preventing exacerbations of chronic bronchitis and COPD.

Authors:  A Ekberg-Jansson; S Larsson; C G Löfdahl
Journal:  BMJ       Date:  2001-05-26

2.  Elastase/LPS-exposed mice exhibit impaired innate immune responses to bacterial challenge: role of scavenger receptor A.

Authors:  Shyamala Ganesan; Andrea N Faris; Adam T Comstock; Joanne Sonstein; Jeffrey L Curtis; Uma S Sajjan
Journal:  Am J Pathol       Date:  2011-11-08       Impact factor: 4.307

3.  Roflumilast (daliresp): a novel phosphodiesterase-4 inhibitor for the treatment of severe chronic obstructive pulmonary disease.

Authors:  Jordan Baye
Journal:  P T       Date:  2012-03

4.  Exposing rodents to a combination of tobacco smoke and lipopolysaccharide results in an exaggerated inflammatory response in the lung.

Authors:  E L Hardaker; M S Freeman; N Dale; P Bahra; F Raza; K H Banner; C Poll
Journal:  Br J Pharmacol       Date:  2010-08       Impact factor: 8.739

Review 5.  Similarities and discrepancies between exacerbations of asthma and chronic obstructive pulmonary disease.

Authors:  L Fabbri; B Beghé; G Caramori; A Papi; M Saetta
Journal:  Thorax       Date:  1998-09       Impact factor: 9.139

6.  HSP90 inhibitor geldanamycin reverts IL-13- and IL-17-induced airway goblet cell metaplasia.

Authors:  Alejandro A Pezzulo; Rosarie A Tudas; Carley G Stewart; Luis G Vargas Buonfiglio; Brian D Lindsay; Peter J Taft; Nicholas D Gansemer; Joseph Zabner
Journal:  J Clin Invest       Date:  2019-01-14       Impact factor: 14.808

7.  A ferret model of COPD-related chronic bronchitis.

Authors:  S Vamsee Raju; Hyunki Kim; Stephen A Byzek; Li Ping Tang; John E Trombley; Patricia Jackson; Lawrence Rasmussen; J Michael Wells; Emily Falk Libby; Erik Dohm; Lindy Winter; Sharon L Samuel; Kurt R Zinn; J Edwin Blalock; Trenton R Schoeb; Mark T Dransfield; Steven M Rowe
Journal:  JCI Insight       Date:  2016-09-22

Review 8.  The role of CLCA proteins in inflammatory airway disease.

Authors:  Anand C Patel; Tom J Brett; Michael J Holtzman
Journal:  Annu Rev Physiol       Date:  2009       Impact factor: 19.318

9.  Imbalances between interleukin-1 and tumor necrosis factor agonists and antagonists in stable COPD.

Authors:  Elizabeth Sapey; Ali Ahmad; Darren Bayley; Paul Newbold; Noel Snell; Paul Rugman; Robert A Stockley
Journal:  J Clin Immunol       Date:  2009-03-17       Impact factor: 8.317

Review 10.  Managing older patients with coexistent asthma and chronic obstructive pulmonary disease: diagnostic and therapeutic challenges.

Authors:  Vanessa M McDonald; Isabel Higgins; Peter G Gibson
Journal:  Drugs Aging       Date:  2013-01       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.